Showing results (71-80 of 94) with videos related to
Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2011
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHERAdam M Brufsky, Musa Mayer, Hope S Rugo, et al.Journal of Ultrasound|March 8, 2024
Morphometry of the sural nerve in diabetic neuropathy: a systematic reviewZhang Ludi, Matthias Yi Quan Liau, Bryan Song Jun Yong, et al.Cancers|August 12, 2023
Trends in Head and Neck Cancer Mortality from 1999 to 2019 in Japan: An Observational AnalysisTsukasa Higashionna, Keisaku Harada, Akinari Maruo, et al.Biorxiv : the Preprint Server for Biology|April 24, 2023
Protective effect of pre-existing natural immunity in a nonhuman primate reinfection model of congenital cytomegalovirus infectionMatilda Moström, Shan Yu, Dollnovan Tran, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31Elizabeth Tan-Chiu, Greg Yothers, Edward Romond, et al.The Review of Scientific Instruments|April 3, 2016
A passive terahertz video camera based on lumped element kinetic inductance detectorsSam Rowe, Enzo Pascale, Simon Doyle, et al.Thorax|May 30, 2025
Effect of elexacaftor/tezacaftor/ivacaftor on systemic inflammation in cystic fibrosisRosemary E Maher, Urszula M Cytlak-Chaudhuri, Saad Aleem, et al.British Journal of Cancer|December 21, 2018
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind studyMark D Pegram, Igor Bondarenko, Marina Moreira Costa Zorzetto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyHoward A Burris, Hope S Rugo, Svetislava J Vukelja, et al.Nature Medicine|July 25, 2018
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancerDarren K Patten, Giacomo Corleone, Balázs Győrffy, et al.Pageof 10